#GV300
Graviton BioScience Unveils Promising Preclinical Data for Treating Multiple Sclerosis with ROCK2 Inhibition#USA#Washington,_D.C.#Multiple_Sclerosis#Graviton_Bioscience#GV300
Graviton BioScience Unveils Promising Preclinical Data for Treating Multiple Sclerosis with ROCK2 Inhibition
Graviton BioScience has announced promising preclinical results showing that its ROCK2 inhibitor GV300 may offer new hope for treating multiple sclerosis by targeting inflammation and promoting CNS repair.
third-news.com
November 16, 2026 at 2:15 PM
Explore the details: https://bit.ly/4t7x5fC

Preclinical studies of experimental MS therapy GV300 showed reduced disease severity and spinal cord inflammation in mice.

#MultipleSclerosis #MS
Experimental MS therapy helps repair damaged myelin in mice
Preclinical studies of experimental MS therapy GV300 showed reduced disease severity and spinal cord inflammation in mice.
bit.ly
November 17, 2026 at 4:47 PM